Multiple myeloma affects predominantly the middle-aged and elderly with an annual incidence of 3 new cases per 100, 000 population (1, 2) . The most common causes of death are uremia and infection. Functional renal insufficiency occurs in about half of the patients and carries a poor prognosis (3) (4) (5) (6) .
Renal failure often appears insiduously and progresses slowly, or less commonly it may come on acutely. A diverse pathogenesis includes light chain tubular toxicity or intratubular precipitaion of light chains (myeloma cast nephropathy), hypercalcemia, hypeuricemia, amyloidosis, nonamyloid paraprotein deposition, hyperviscosity, cryoglobulinemia, urinary tract obstruction, pyelonephritis, exposure to radiocontrast agents, and nephrotoxic drugs (6) (7) (8) (9) . The most common cause, however, is myeloma cast nephropathy or hypercalcemia, with intravascular volume depletion as an associated condition. Patients with renal insufficiency should be evaluated and treated for reversible components such as volume depletion, hyperuricemia, hypercalcemia, pyelonephritis, and increased plasma viscosity. Supportive management designed to correct volume depletion and to reduce M-protein nephrotoxicity may improve renal function (10) (11) (12) (13) (14) (15) (16) . Specific recommendations include hydration and alkaline diuresis using saline infusions, furosemide, and sodium bicarbonate. Chemotherapy (generally with melphalan and prednisone) and even plasmapheresis may reduce the M-protein load. Management of coexisting hypercalcemia, hyperuricemia, and infection has also been associated with improvement. Unfortunately, however, most patients with renal failure do not improve. Yet the occasional delayed reversal of myeloma cast nephropathy has occurred following a prolonged period on dialysis (17, 18) . Patients w~th myeloma and renal failure managed conservatively without dialysis support rarely survive and usually die within 2 months (4, 6) . With the wide use of dialysis, however, morẽ atients are now being supported. In spite of this, the pub-IIs.hed experience regarding dialysis support in myeloma is f al r~y limited. Leech et al. were the first to report on the use of ma~ntenance hemodialysis in two patients in 1972 (19) . Both patients adjusted well and were rehabilitated and able to return to work. One patient lived 44 months, the other 45 onths.
Our own experience in seven patients was also Eavorable (20) . All patients had dialysis and chemotherapy. ven though two of the patients died within three months, median survival was 17 months and there was pronounced subjective improvement. The complicated course in the two patients who died within three months from granulocytopenia and sepsis was probably due to inadequate dialysis and over aggressive chemotherapy. Some reduction in the dose of melphalan or cyclophosphamide seems necessary because bone marrow suppression from cytotoxic drugs in renal failure may be particularly overwhelming. In four additional studies on long-term dialysis in myeloma (4, 21-23), most patients had substantial relief of symptoms and also had prolongation of life of reasonable quality. Rehabilitation was comparable to that of dialysis patients without myeloma, though with considerably shorter survival. A few patients, however, survived up to seven years. Overall, myeloma patients supported with maintenance dialysis and treated with chemotherapy have a 1 year survival, comparable to that of myeloma patients without renal failure. This would indicate a similar response rate to chemotherapy in the two groups. Ultimately the survival in myeloma depends on tumor mass. A large tumor mass correlated with: (a) hemoglobin values below 8.5 mg/dl; (b) serum calcium exceeding 12 mg/dl; (c) advanced lytic bone lesions and (d) high serum M-protein levels (24) . Because uremia can affect independently several ofthese factor, caution is needed in assessing a myeloma patient with associated renal failure. However, it has been recently shown that a high serum calcium correlates negatively with survival in myeloma patients with uremia (22) . Extensive bone disease and marrow plasmacytosis of greater than 35% have also been shown to correlate with decreased survival (21) . In addition, the greatest risk for serious infection appears to be within the first two months after beginning chemotherapy (25) . The limited experience with peritoneal dialysis in multiple myeloma has also been favorable and suggests it may be as effective as hemodialysis (4, (26) (27) (28) . It also has the advantage of removing M-proteins from the circulation. Plasmapheresis, however, remains the most efficient tool for rapidly removing light chains from plasma (16, 29) . As there are no available data to suggest any overall advantage of peritoneal hemodialysis, the choice of dialysis should be individualized. Renal transplantation seems to be a reasonable consideration when extrarenal disease is well controlled. This is because: (a)transplantation generally allows a better degree of of rehabilitation; (b) it leads to rapid correction of anemia; (c) antitumor drug regimens generally assure adequate immunosuppression to prevent rejection and (d) improved renal function affords better elimination of calcium, phosphorous, uric acid and paraproteins that may undergo tissue deposition and/or adversely affect other organ systems. Yet a number of reservations and questions remain: (a) Is the effort and expense justifiable in patients with a very limited life expectancy and rehabilitation potential? (b) With the shortage oftransplantable kidneys what priority should be given to patients with myeloma? (c) Will recurrence of disease shorten allograft survival? (d) Can transplant immunosuppression promote growth or spread ofthe tumor? As present experience is quite limited, the above issues cannot be addressed clearly. In five reported cases survival was 14 months, 15 months, 18 0391-3988/600317-02 $00.50/0 months, 42 months and 9.5 years post-transplantation (9, (30) (31) (32) (33) . The primary cause of death was always overwhelming infection with sepsis. Another patient has been reported to be alive and well about 3 1 /2 years after transplantation (34) . Interestingly, no significant deterioration in renal function was noted spite of myeloma allograft involvement in three of the cases. Although the current data is not sufficient to permit determination of an optional chemotherapeutic regimen, prednisone in combination with cyclophosphamide has been effective both in suppressing myeloma and in preventing graft rejection. In addition, melphalan can be substituted for cyclophosphamide during brief treatment periods without compromising graft function. Overall, the reported experience with renal transplantation in myeloma has been very favorable, with a median survival of approximately 41 months. This compares favorably with the median survival of 40 months in myeloma patients without renal insufficiency who responded to chemotherapy (35) . Obviously, one must interpret the myeloma transplantation results with caution, as these data are from a small number of highly selected patients. One must also keep in mind that a favorable outcome tends to be reported more frequently. Yet clearly, in selected patients who have responded well to chemotherapy and do not have extensive extrarenal tumor involvement, prolonged survival of a good quality can be achieved. In conclusion, supportive dialysis and chemotherapy can be generally recommended in multiple myeloma because the patients so treated have survival rates comparable to those without renal failure. With relief of the symptoms of uremic and myeloma, a substantial degree of rehabilitation should be achievable. Experience with renal transplantation has also been quite favorable, and may be considered in stable motivated patients without extensive or progressive tumor involvement.
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